Clinical Trial Update: Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Hyper-CVAD plus Imatinib Mesylate for Philadelphia chromosome-positive acute lymphoblastic leukemia; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Hyper-CVAD
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-09-18